Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 9;15:55–67. doi: 10.2147/LCTT.S455034

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 González-Cao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effect of antiretroviral and selinexor treatment on cell viability analyzed by Cell Counting Kit-8 assay. (A) Effect of 20 uM single selinexor or antiretroviral treatments on cell viability in the H520, PC9, A549 and H1975 lung cancer cell lines, compared to the control. (B) Effect of single and combined selinexor plus osimertinib or erlotinib treatment on cell viability in the H1975 cell line, using different concentrations of selinexor. (C) Effect of single and combined selinexor plus osimertinib or erlotinib treatment on cell viability in the PC9 cell line, using different concentrations of selinexor. (D) Effect of single and combined selinexor plus MEK-inhibition treatment on cell viability in the A549 cell line, using different concentrations of selinexor. (E) Effect of single and combined selinexor plus MEK-inhibition treatment on cell viability in the H460 cell line, using different concentrations of selinexor. Data were analyzed using unpaired t-test comparisons. *P <0.05, **P <0.01, compared to control. ^#P <0.05, ^##P <0.01, comparison between two groups marked with horizontal lines.